Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Exclusion criteria

• ✕. Known severe hypersensitivity (≥Grade 3) to any monoclonal/polyclonal antibody, chidamide, or anlotinib components.
• ✕. Necrotic lesions identified within 4 weeks prior to enrollment, with investigator-judged risk of major bleeding.
• ✕. Chemotherapy, targeted therapy, or immunomodulatory agents (including thymosin, interferon, IL-2, etc.) within 2 weeks prior to enrollment.
• ✕. Palliative radiotherapy to localized lesions within 4 weeks prior to enrollment, unless the lesion is non-target and other measurable target lesions exist.
• ✕. Grade ≥3 irAEs during prior immunotherapy.
• ✕. Prior treatment with HDAC inhibitors or anti-angiogenic agents.
• ✕. Urine protein ≥2+ or 24-hour urinary protein ≥1 g.
• ✕. Systolic BP \>140 mmHg or diastolic BP \>90 mmHg despite treatment.